Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
Authors
Oh, D. Y.He, A. R.
Qin, S.
Chen, L. T.
Okusaka, T.
Vogel, A.
Kim, J. W.
Suksombooncharoen, T.
Lee, M. A.
Kitano, M.
Burris, H. A.
Bouattour, M.
Tanasanvimon, S.
Zaucha, R. E.
Avallone, A.
Cundom, J. E.
Rokutanda, N.
Watras, M.
Cohen, G.
Valle, Juan W
Affiliation
Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of KoreaIssue Date
2022
Metadata
Show full item recordCitation
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC). Annals of Oncology. 2022 Sep;33(7):S565-S6. PubMed PMID: WOS:000866211600056.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.10.114Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.10.114Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.10.114